NCT05615948 - Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 6, 2022

Primary Completion Date

May 17, 2024

Study Completion Date

May 17, 2024

Conditions

Treatment Resistant DepressionMajor Depressive DisorderAnalgesiaKetaminePeripheral Nervous System AgentsCentral Nervous System DepressantsNeurotransmitter AgentsAnti-Inflammatory AgentsPhysiological Effects of DrugsSensory System AgentsAnalgesics, Non-NarcoticAnti-Inflammatory Agents, Non-SteroidalDepressive Symptoms

Interventions

DRUG

VTS-K

Proprietary oral formulation of 486mg aspirin and 80mg ketamine

Trial Locations (1)

11219

Maimonides Medical Center, Brooklyn